GRCE
Grace Therapeutics, Inc.Company with tickers: GRCE
CIK
1444192
CUSIP
00439U104
Shares Outstanding
15,474,026
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $1,985,000 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| Operating Income | $-8,067,000 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| Net Income | $-6,615,000 | USD | 2025-12-31 | 10-Q | 2026-02-12 |
| EPS (Basic) | $-0.41 | USD/shares | 2025-12-31 | 10-Q | 2026-02-12 |
| EPS (Diluted) | $-0.41 | USD/shares | 2025-12-31 | 10-Q | 2026-02-12 |